Format

Send to:

Choose Destination
See comment in PubMed Commons below
Appl Microbiol Biotechnol. 2013 Feb;97(3):1231-9. doi: 10.1007/s00253-012-4575-1. Epub 2012 Dec 5.

Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface.

Author information

  • 1Commensal and Probiotics-Host Interactions Laboratory, INRA, UMR 1319 Micalis, 78350, Jouy-en-Josas, France.

Erratum in

  • Appl Microbiol Biotechnol. 2013 Feb;97(3):1395. Riazi, Ali [removed].

Abstract

Human papillomavirus (HPV) is the causative agent of cervical cancer (CxCa) and the most commonly sexually transmitted pathogen worldwide. HPV type 16 (HPV-16) E7 oncoprotein is constitutively produced in CxCa and considered as a good antigen candidate for the development of new therapeutic CxCa vaccines. Here, we report the use of non-genetically modified, E7-expressing lactic acid bacteria (LAB) by using the cell-binding domain from Lactobacillus casei A2 phage lysin as a cell wall anchor. The versatility of this system was validated by investigating E7 stability at the surface of Lactococcus lactis and L. casei, two major species of LAB. Moreover, we demonstrated the successful use of these LAB displaying E7 antigen as a mucosal live vaccine in mice. Altogether, these results show the feasibility of using non-genetically modified LAB for low-cost mucosal immunotherapy against HPV-related CxCa in humans.

PMID:
23212671
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk